Auris Medical Receives Notice of Allowance for US and European Patent Applications

- September 11th, 2019

Auris Medical Holding (NASDAQ:EARS) has announced that the US Patent and Trademark Office (USPTO) has issued a notice of allowance for its patent application as well the receipt of an intention to grant notice from the European Patent Office. As quoted in the press release: Upon issuance, the patents are expected to expire no earlier … Continued

Auris Medical Holding (NASDAQ:EARS) has announced that the US Patent and Trademark Office (USPTO) has issued a notice of allowance for its patent application as well the receipt of an intention to grant notice from the European Patent Office.

As quoted in the press release:

Upon issuance, the patents are expected to expire no earlier than February 2038 and will provide key intellectual property protection for the Company’s intranasal betahistine program.

The allowed claims cover composition of matter and methods of use for formulations of betahistine dihydrochloride for intranasal delivery. The communications from the USPTO and EPO conclude substantive examination of the patent applications, which are now expected to issue as patents once the issue fees are paid and the patent offices conclude their respective administrative procedures. Auris Medical also has filed corresponding patent applications that will allow the Company to seek similar patent protection in other key markets throughout the world.

“We are very pleased to have achieved this major milestone in the protection of our intellectual property around the intranasal betahistine program“, commented Thomas Meyer, Auris Medical’s founder, Chairman and CEO. “The intranasal delivery route allows for a surprisingly strong increase in betahistine concentration in the bloodstream compared to the common oral route, which is expected to result in superior therapeutic benefits. We look forward to developing this innovation further in order to help patients who are suffering from vertigo or antipsychotic-induced weight gain, among other potential medical conditions.”

Click here to read the full press release.

Is the biotech market the perfect mesh between the technology and pharmaceutical market?

 
Read our FREE outlook report below!
 

Get the latest Biotech Investing stock information

Get the latest information about companies associated with Biotech Investing Delivered directly to your inbox.

Biotech Investing

Select All
Select None

Leave a Reply

Your email address will not be published. Required fields are marked *